Are Mediclinic International plc, AstraZeneca plc and Smith & Nephew plc the best FTSE 100 healthcare picks?

G A Chester puts Mediclinic International plc (LON:MDC), AstraZeneca plc (LON:AZN) and Smith & Nephew plc (LON:SN) under the spotlight.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Mediclinic International (LSE: MDC) was formed earlier this year when Abu Dhabi-based FTSE 250 firm Al Noor Hospitals combined with South African company Mediclinic. The enlarged private healthcare group was promoted to the FTSE 100 and released its first results this morning.

Strong growth drivers

Mediclinic reported increased patient volumes leading to a 7% rise in revenue to £2.1bn from its 73 hospitals and 45 clinics in South Africa, Namibia, Switzerland and the UAE. Underlying earnings per share increased 3% to 36.7p.

The company, which also has a 29.9% stake in UK firm Spire Healthcare, said: “We anticipate continued capacity and footprint expansion at attractive returns across all of our operating platforms. The Group is well positioned to deliver long-term value to our shareholders”.

The results and generally upbeat outlook saw the shares head 2% higher in early trading, although management did note a continuing impact on the business of “on-going regulatory initiatives and increasing competition”.

However, the long-term growth drivers for the industry are strong, and Mediclinic’s earnings should also get a short-term shot in the arm from the immediate synergies and cost efficiencies of its enlarged scale. As such, I would say the company merits its premium trailing price-to-earnings (P/E) ratio of 23.6.

Income appetiser

Shareholders of pharmaceuticals firm AstraZeneca (LSE: AZN) have endured a long period of frustration, as expiring patents have hit the company’s top and bottom lines. With the shares currently trading below 4,000p, some shareholders probably now wish the board had accepted a 5,500p offer from US group Pfizer two years ago.

However, while Astra isn’t quite out of the woods yet, the future looks bright, with chief executive Pascal Soriot having refocused the business and the drugs pipeline now looking very strong. The long period of revenue and earnings declines appears set to bottom out next year, and management’s medium-term outlook suggests we’ll see impressive growth thereafter.

Trading on 15 times next year’s bottom-of-the-trough forecast earnings, Astra looks an appealing investment with a 5% dividend yield as a nice appetiser ahead of the prospect of strong capital and income increases in the medium term.

Consistent performer

Smith & Nephew (LSE: SN) offers exposure to a third area of the broadly attractive healthcare sector. With its sports medicine, knee and hip implants and advanced wound management divisions, the group is well placed to benefit from such trends as healthier lifestyles and ageing populations are keen to enjoy an active retirement.

S&N has delivered consistent earnings and dividend growth over many years and the pattern is set to continue. Current-year forecasts put the company on a P/E of 19.5, falling to 17.5 for 2017 on the back of 12% forecast earnings growth. The stock looks very buyable to me, with the rating appearing more than reasonable for such a consistent performer in an industry with attractive long-term dynamics.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »